Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration

被引:13
作者
Moreno, Julie A. [1 ]
Mallucci, Giovanna R. [1 ]
机构
[1] Univ Leicester, MRC Toxicol Unit, Leicester LE1 9EH, Leics, England
基金
英国医学研究理事会;
关键词
behaviour; neurodegeneration; neurophysiology; prion protein (PrP); synaptic dysfunction; LONG-TERM POTENTIATION; TRANSGENIC MICE; IN-VIVO; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; ADULT NEOCORTEX; MOUSE MODEL; SPINE LOSS; PROTEIN;
D O I
10.1042/BST0380482
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synaptic dysfunction is a key early process in many neurodegenerative diseases, but how this ultimately leads to neuronal loss is not clear. In health, there is ongoing remodelling of synapses and spines in the adult brain: their elimination and formation are continual physiological processes fundamental to learning and memory. But in neurodegenerative disease, including prion disease, lost synapses are not replaced, and their loss is followed by neuronal death. These two processes are separately regulated, with mechanistic, spatial and temporal segregation of the respective death routines of synapses and cell bodies. Mice with prion disease can be cured at the stage of early synaptic dysfunction, when they have reversible impairments at neurophysiological, behavioural and morphological levels. Critically, reversing synaptic dysfunction at this stage of disease rescues neurons, preventing its otherwise inevitable progression to synapse loss and cell death. These findings call for a deeper analysis of the mechanisms underlying neurotoxicity at the synapse, and have important implications for the therapy of prion and other neurodegenerative disorders.
引用
收藏
页码:482 / 487
页数:6
相关论文
共 37 条
  • [31] Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model
    Spires-Jones, Tara L.
    Meyer-Luehmann, Melanie
    Osetek, Jennifer D.
    Jones, Phillip B.
    Stern, Edward A.
    Bacskai, Brian J.
    Hyman, Bradley T.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2007, 171 (04) : 1304 - 1311
  • [32] Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
    Walsh, DM
    Klyubin, I
    Fadeeva, JV
    Cullen, WK
    Anwyl, R
    Wolfe, MS
    Rowan, MJ
    Selkoe, DJ
    [J]. NATURE, 2002, 416 (6880) : 535 - 539
  • [33] Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus
    Wang, HW
    Pasternak, JF
    Kuo, H
    Ristic, H
    Lambert, MP
    Chromy, B
    Viola, KL
    Klein, WL
    Stine, WB
    Krafft, GA
    Trommer, BL
    [J]. BRAIN RESEARCH, 2002, 924 (02) : 133 - 140
  • [34] Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease
    White, Melanie D.
    Farmer, Michael
    Mirabile, Ilaria
    Brandner, Sebastian
    Collinge, John
    Mallucci, Giovanna R.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (29) : 10238 - 10243
  • [35] RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
    White, Melanie D.
    Mallucci, Giovanna R.
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (05) : 342 - 352
  • [36] Therapy for prion diseases Insights from the use of RNA interference
    White, Melanie D.
    Mallucci, Giovanna R.
    [J]. PRION, 2009, 3 (03) : 121 - 128
  • [37] Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
    Yamamoto, A
    Lucas, JJ
    Hen, R
    [J]. CELL, 2000, 101 (01) : 57 - 66